ImmuneOncia Therapeutics, Inc. (KOSDAQ:424870)

South Korea flag South Korea · Delayed Price · Currency is KRW
7,110.00
-140.00 (-1.93%)
At close: Apr 28, 2026
Market Cap 528.73B
Revenue (ttm) 111.21M
Net Income (ttm) -27.36B
Shares Out 74.36M
EPS (ttm) -390.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 145,933
Average Volume 291,624
Open 7,210.00
Previous Close 7,250.00
Day's Range 7,070.00 - 7,210.00
52-Week Range 4,455.00 - 16,110.00
Beta n/a
RSI 39.30
Earnings Date n/a

About ImmuneOncia Therapeutics

ImmuneOncia Therapeutics, Inc., an immuno-oncology-centric biopharmaceutical company, develops immuno-oncology drugs for the treatment of cancer. It develops IMC-001, a human monoclonal antibody of the IgG1 type that targets PD-L1 an immunotherapy for cancer, which is in Phase II clinical trial for the treatment of NK/T cell lymphoma and solid cancer patients with high tumor mutation burden; and IMC-002, a human monoclonal antibody of the IgG4 type targeting human CD47, which is in Phase I a clinical trial for the treatment of solid cancers, su... [Read more]

Industry Pharmaceutical Preparations
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 424870
Full Company Profile

Financial Performance

In 2025, ImmuneOncia Therapeutics's revenue was 111.21 million, a decrease of -83.01% compared to the previous year's 654.54 million. Losses were -27.36 billion, 381.2% more than in 2024.

Financial Statements

News

There is no news available yet.